Fas and Fas ligand expression in maternal blood and in umbilical cord blood in preeclampsia

Pediatric Research

Volumn 50, Issue 6, 2001, Pages 743-749

  Kuntz, Tracey B ^a   Christensen, Robert D ^a   Stegner, Joseph ^a   Duff, Patrick ^a   Koenig, Joyce M ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GESTATIONAL AGE; HUMAN; IMMUNOLOGICAL TOLERANCE; INFANT; INFLAMMATION; LEUKOCYTE; LYMPHOCYTE; MATERNAL BLOOD; MORBIDITY; NEUTROPHIL; NEWBORN; NEWBORN CARE; PATHOGENESIS; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TROPHOBLAST; UMBILICAL CORD BLOOD;

EID: 0035195745     PISSN: 00313998     EISSN: None     Source Type: Journal    
DOI: 10.1203/00006450-200112000-00019     Document Type: Article

References (57)

1. Fas ligand-induced apoptosis
2. Fas ligand-induced apoptosis as a mechanism of immune privilege
3. Apoptosis, graft rejection, and transplantation tolerance
4. Multiple inhibitory cytokines induce deregulated progenitor growth and apoptosis in hematopoietic cells from Fac-/- mice
5. Cell death induced by the Fas/Fas ligand pathway and its role in pathology
6. Chronic neutropenia mediated by fas ligand
7. Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus
8. Trophoblasts express Fas ligand: A proposed mechanism for immune privilege in placenta and maternal invasion
9. Multiple mechanisms of peripheral T cell tolerance to the fetal "allograft"
10. Placental Fas ligand expression is a mechanism for maternal immune tolerance to the fetus
11. The role of placental Fas ligand in maintaining immune privilege at maternal-fetal interfaces
12. Immune aspects of pathology of the placental bed contributing to pregnancy pathology
13. Interleukin-1 beta, human leukocyte antigen HLA-DR alpha, and transforming growth factor-beta expression in endometrium, placenta, and placental membranes
14. Susceptibility of human trophoblast to killing by human complement and the role of the complement regulatory proteins
15. Hypertension and pregnancy-related hypertension
16. Neonatal manifestations of severe maternal hypertension occurring before the thirty-sixth week of pregnancy
17. Incidence, neutrophil kinetics, and natural history of neonatal neutropenia associated with maternal hypertension
18. Circulating factors as markers and mediators of endothelial cell dysfunction in preeclampsia
19. Matemal-placental interactions of oxidative stress and antioxidants in preeclampsia
20. Preeclampsia: An excessive maternal inflammatory response to pregnancy
21. Paternal and maternal components of the predisposition to preeclampsia
22. Review: Immunobiology of preeclampsia
23. The neutrophil and preeclampsia
24. Enhanced expression of Fas-associated proteins in decidual and trophoblastic tissue in pregnancy-induced hypertension
25. Fas ligand in human serum
26. Increased soluble Fas-ligand in sera of bone marrow transplant recipients with acute graft-versus-host disease
27. Fas and Fas ligand expression on human peripheral blood leukocytes
28. ACOG technical bulletin. Hypertension in pregnancy. Number 219-January 1996
29. Spontaneous and Fas-mediated apoptosis are diminished in umbilical cord blood neutrophils compared with adult neutrophils
30. Revised reference ranges for circulating neutrophils in very-low-birth-weight neonates
31. The metalloproteinase matrilysin proteolytically generates active soluble fas ligand and potentiates epithelial cell apoptosis
32. Collagenase-1, stromelysin-I, and matrilysin are expressed within the placenta during multiple stages of human pregnancy
33. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: Implications for the regulation of apoptosis in neutrophils
34. Maternal second trimester serum tumor necrosis factor-alpha-soluble receptor p55 (sTNFp55) and subsequent risk of preeclampsia
35. Clinical and biochemical evidence of endothetial cell dysfunction in the pregnancy syndrome preeclampsia
36. Expression of matrix metalloproteinase 7 (matrilysin) in human osteoarthritic cartilage
37. Effect of magnesium sulfate pretreatment and significance of matrix metalloproteinase-1 and interleukin-6 levels in coronary reperfusion therapy for patients with acute myocardial infarction
38. Regulation of bcl-2 and fas expression in primary activation of human peripheral lymphocytes is not sensitive to dexamethasone or cyclosporin-A
39. Dexamethasone induces apoptosis in human T cell clones expressing low levels of Bcl-2
40. Cytokine release from placental endothelial cells, a process associated with preterm labour in the absence of intrauterine infection
41. Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles
42. Release of preformed Fas ligand in soluble form is the major factor for activation-induced death of Jurkat T cells
43. Fas and Fas ligand in gut and liver
44. Downregulation of Fas ligand by shedding
45. Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes
46. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction
47. Accelerated rejection of Fas ligand-expressing heart grafts
48. The mechanism responsible for diminished neutrophil production in neonates delivered of women with pregnancy-induced hypertension
49. Apoptotic role of Fas/Fas ligand system in the regulation of erythropoiesis
50. Serum soluble Fas levels in preeclampsia
51. Lymphocyte activation in health and disease
52. Expression and function of Fas and Fas ligand on peripheral blood lymphocytes in normal subjects
53. Apoptosis, Fas and systemic autoimmunity: The MRL-lpr/lpr model
54. Fas-deficient lpr mice are more susceptible to graft-versus-host disease
55. Promotion of neutrophil apoptosis by TNF-alpha
56. Antigen presenting cells expressing Fas ligand down-modulate chronic inflammatory disease in Fas ligand-deficient mice